Efavirenz indications and usage

Efavirenz
SUSTIVA^® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Indications and Usage

SUSTIVA® (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.^[1]

References

↑ "SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB PHARMA COMPANY]".

Adapted from the FDA Package Insert.

[dailymed.nlm.nih.gov-1] "SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) CAPSULE, GELATIN COATED SUSTIVA (EFAVIRENZ) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB PHARMA COMPANY]".

[1]

Efavirenz indications and usage

Indications and Usage

References

Navigation menu

Search